BioSyngen Pte Ltd Report issue

For profit Phase 1 Phase 2
Founded: Singapore Singapore (2016)

Organization Overview

First Clinical Trial
2019
NCT03736122
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

BioSyngen Australia Pty Ltd | BioSyngen Pte Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

syngenon (1 trial)

Drugs in Phase 1 Trials (1)

BST02 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ascites (Phase 2)

Pleural Effusion (Phase 2)

Pleural Effusion, Malignant (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2